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ABSTRACT
In this review article we describe the ante- and perinatal management of fetal neck tumors. Although there are rare con-
genital anomalies, the clinical consequences for the fetus may be fatal and include airways obstruction, heart insufficiency, 
pulmonary hypoplasia and cosmetic effect. The right management allows to decrease the fetal and neonatal mortality 
and morbidity associated with the disease. It includes intrauterine therapy in some cases, mostly in a goitrus hypothyroid-
ism of the fetus, but firstly, an assessment of the fetal airways patency with a subsequent, eventual Ex-Utero Intrapartum 
Treatment (EXIT).
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INTRODUCTION
Fetal tumors are very rare congenital anomalies. Their 
incidence is around 1 in 12 000 to 1 in 30 000 births [1]. 
Among them, neck tumors represent an important group. 
This is a very specific and unique fetal and neonatal prob-
lem. Initially, like other fetal tumors, neck masses may 
negatively affect the fetal cardiac function because of 
increased cardiac afterload and preload. Secondly, they 
may affect the patency of fetal airways, including trachea, 
which may have fatal consequences after birth. In addition, 
big neck tumors, especially teratomas, may cause fetal 
lung hypoplasia, because of wedging the lungs into the 
apices of chest cavity [2]. Finally, they have great cosmetic 
effect on the child.
A differential diagnosis of the fetal neck tumor or cystic 
lesions include lymphangioma, haemangioma, goiter, tera-
toma and neuroblastoma [2, 3]. 
The aim of this review is to bring together the topic of 
fetal neck tumors, especially the importance of their clinical 
antenatal and peripartum management to decrease the 
fetal and neonatal morbidity and mortality. 
ANTENATAL MANAGEMENT OF FETAL NECK 
TUMORS AND DIFFERENTIAL DIAGNOSIS
The antenatal management of fetal neck tumors in-
cludes primarily the diagnosis. This can be achieved using 2D 
ultrasound. Some additional information may be obtained 
through MRI, especially if a significant part of the tumor 
is intracorporeal. Three dimensional (3D) ultrasound has 
a limited role in diagnosis and management of fetal neck 
tumors. For further monitoring of the mass it is very impor-
tant to measure its dimensions (at least the length and the 
width). Both ultrasound and magnetic resonance imaging 
(MRI) enable the differentiation between solid or partly 
solid tumors such as fetal goiter (Fig. 1), teratoma (Fig. 2) or 
neuroblastoma and cystic or multicystic lesions like lym-
phangioma (Fig. 3) and hemangioma. In comparison to solid, 
hyperechoic and regular character of goiter, echogenicity 
of teratoma is usually more heterogenic with both solid 
and cystic components. Neck is a very rare localization of 
neuroblastoma. Differential diagnosis of lymphangioma and 
hemangioma includes an assessment of cystic content of 
the tumor. It is much more hyperechoic in hemangioma. An 
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ultrasound assessment of the mass should also include the 
vascularization of the tumor. The solid masses, like goiter, ter-
atoma, or neuroblastoma may be highly vascularized (Fig. 4). 
In such a case there is an increased risk of a development 
of a heart failure in the fetus because of increased preload. 
Therefore, in all the cases of fetal neck masses, especially 
in solid or partly solid ones, a precise echocardiographic 
assessment should be done. Previously, we reported a case 
on a fetus with a large goiter who had to be delivered at 
29 weeks due to signs of heart failure, including hydrops [3]. 
Summary of ultrasound features of different types of neck 
masses is presented in Table 1. Another important aspect 
of antenatal management of fetal neck tumors is an as-
sessment of amniotic fluid volume. The increase of Amni-
otic Fluid Index (AFI) and development of polyhydramnios 
indicate on impaired fetal swallowing as a consequence of 
esophagus and trachea displacement and compression. In 
case of development of severe polyhydramnios causing 
preterm contractions and patient’s dyspnea amnioreduc-
tion may be required. It may decrease the risk of preterm 
Table 1. Ultrasound features of different types of fetal neck masses 
Type Character Echogenicity Vascularization
Goiter Solid Hyperechogenic High
Teratoma Solid/cystic Hyper/hypoechogenic Variable
Lymphangioma Cystic Hypoechogenic Poor
Hemangioma Cystic Hyperechogenic High
Neuroblastoma Solid/cystic Hyper/hypoechogenic Variable
Figure 1. A longitudinal scan of a fetus with a goiter at 20 weeks 
gestation 
Figure 3. A fetal neck lymphangioma 
Figure 2. A longitudinal scan of a fetus with a neck teratoma 
Figure 4. A transverse view of the fetus with a highly vascularized 
goiter 
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labor that has a direct effect on neonatal mortality and 
morbidity. For a fetal goiter described, we performed one 
amnioreduction due to AFI (Amniotic Fluid Index) of 27 cm 
and the presence of patient’s dyspnea.  
INTRAUTERINE THERAPY
An antenatal differential diagnosis of the fetal neck tu-
mors may also be crucial for the further management of the 
fetus, including an intrauterine therapy. Mainly, this is pos-
sible for diagnosis of fetal goitrous hypothyroidism. There 
are several reports on the successful intrauterine treatment 
of goitrous hypothyroidism with repeated intraamniotic in-
jection of L-thyroxine [3–10]. Such a treatment must follow 
the precise ultrasound assessment of the mass and, impor-
tantly, an amniocentesis to obtain the results of TSH, fT3 and 
fT4 concentrations in the amniotic fluid. The reference 
ranges have been established for thyroid hormones’ con-
centrations in amniotic fluid, most recently by Singh et al. 
in 2003 and Baumann and Gronowski in 2007 [11, 12]. In 
the biggest study, described by Ribault et al., 12 fetuses 
were treated antenatally with intraamniotic injections of 
L-thyroxine for goitrous hypothyroidism [10]. In all except 
one of these fetuses, goiter size decrease was observed 
after the therapy. In the case described by us, eight in-
traamniotic injections of L-thyroxine were given from 23 to 
37 weeks of gestation [3]. A significant reduction in goiter 
size was noted, as well as normalization of the TSH level in 
amniotic fluid, and improvement in the primarily impaired 
cardiac function. The above examples confirm a rather good 
prognosis for a diagnosis of fetal goiter. This advantageous 
prognosis means a reduction in goiter size with positive 
consequences on high airways patency and cardiac func-
tion. However, an effective intrauterine treatment of the 
fetal goiter does not prevent hypothyroidism after birth. 
Most of the affected children require further therapy with 
L-thyroxine [3, 10]. The dosage of L-thyroxine usually used 
for the antenatal treatment are 200–800 micrograms per 
injection.
A second type of fetal neck tumor which may be pos-
sibly treated antenatally is a lymphangioma. The proposed 
method of therapy with OK-432 (sclerotherapy) injected 
into the neck mass in two fetuses was presented by Miko-
vic et al. [13]. In both cases a significant decrease in tumor 
size was noted. The above study is the only one describing 
the effective treatment of fetal neck lymphangiomas with 
OK-432. However, this method is widely used postnatally 
by pediatric surgeons. Our limited experience do not con-
firm the effectiveness of such therapy in case of congeni-
tal neck lymphangioma. In a similar case treated by us no 
significant reduction in the mass size was found despite 
significantly increased echogenicity of a tumor after the 
procedure (Fig. 5) [14]. 
The most difficult but feasible method of intrauterine 
therapy of fetal neck masses is open fetal tumor resection. 
It may be indicated in a previable fetus with signs of heart 
failure, including hydrops, because of increased pre- and 
afterload of the heart. Such procedure was successfully 
performed by Hirose et al. in one fetus with giant neck 
teratoma [15].
ANTEPARTUM AND INTRAPARTUM 
MANAGEMENT 
Usually, the most important element of antenatal man-
agement of fetal neck tumors is a prediction of fetal airway 
obstruction. This can be achieved with an ultrasound, MRI 
or even directly by fetoscopy [16–18]. The proposed pre-
dictors of a fetal airways obstruction are: polyhydramnios, 
bigger size of the mass, and a presence of teratoma [16]. 
The additional factor predicting the fetal airway obstruc-
tion, called TEDI (tracheoesophageal displacement index) 
was proposed by Lazar et al. [16]. The index is defined as 
a sum of lateral and ventral displacements of the tracheo- 
esophageal complex found on fetal MRI scans [16]. TEDI of 
12 mm or greater is found to be predictive of fetal airway 
obstruction [16].
In each case of fetal neck tumor with suspicion of airway 
obstruction a caesarean section with EXIT (Ex-Utero Intra-
partum Treatment) procedure should be scheduled. EXIT 
consists of a delivery of a head, arms and a thorax of a fetus 
during C-section and a subsequent securement of the pa-
tency of fetal airways via intubation, laryngoscopy or bron-
choscopy and eventually tracheostomy (Fig. 6). At the same 
time the placental support of the fetus is maintained. This 
procedure, which prevents newborn’s respiratory insufficien-
cy, significantly decreased mortality of these patients [19]. 
Very rarely, the tumor, especially bigger one, may be even 
partly resected during EXIT procedure [15, 19]. The whole 
procedure, including the maintenance of placental support 
Figure 5. A fetal neck lymphangioma (3 weeks after intrauterine 
treatment by OK-432 injection)
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of the fetus, requires adequate uterine muscle relaxation 
which is only possible through deep maternal anaesthesia 
[19, 20]. During the procedure fetal life parameters should 
be monitored with a pulse oximeter and an intraoperative 
echocardiography. 
The innovative, alternative method to EXIT may be fetal 
endoscopic tracheal intubation (FETI) [17]. The procedure 
consists of fetal tracheoscopy with subsequent insertion 
of intrauterine orotracheal cannula under ultrasound guid-
ance. This complicated procedure ensures fetal tracheal 
permeability before delivery. The above procedure was de-
scribed by Cruz-Martinez et al. for giant neck teratoma [17].
SUMMARY 
Fetal neck tumors are very rare congenital anoma-
lies. A differential diagnosis includes lymphangiomas, 
hemangiomas, teratomas, goiter and neuroblastoma. In 
individual cases an intrauterine therapy of masses is pos-
sible. It concerns mainly a goiter, but also may be proposed 
in teratoma and lymphangioma. The most important ele-
ment of antenatal management of fetal neck tumors is the 
prediction of fetal airway obstruction. This can be achieved 
with ultrasound, magnetic resonance imaging (MRI), or feto- 
scopy/tracheoscopy. In most  cases of fetal neck masses ce-
sarean section with Ex-Utero Intrapartum Treatment (EXIT) 
procedure should be scheduled. It allows to avoid the most 
dangerous perinatal complication which is fetal/neonatal 
airways obstruction.  
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